• Profile

Incident peptic ulcers and concomitant treatment of direct oral anticoagulants and oral bisphosphonates—A real-world cohort study

Osteoporosis International Feb 01, 2022

In view of the correlation of oral bisphosphonates (oBP) and direct oral anticoagulants (DOAC) with upper gastrointestinal ulcers, researchers sought to determine if the risk of upper gastrointestinal ulcers increases with their concomitant use.

  • In this population-based cohort study, a cohort of oBP and DOAC users from a sample of 2,622,742 individuals, consisting of diabetes patients, and age- and gender-matched controls, were assessed.

  • Concomitant treatment with DOAC and oBP was received by 8,077 individuals; 96,451 individuals used DOAC and no oBP; and 118,675 used oBP and no DOAC.

  • On exclusion of individuals with previous upper gastrointestinal ulcers, there appeared no increased risk of upper gastrointestinal ulcers in correlation with receiving concomitant treatment compared with the use of either drug alone.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen